Market News

Sector Gamma As Lowered Impax Laboratories (IPXL) Position By $3.34 Million; Devon Energy (DVN)’s Sentiment Is 1

Sector Gamma As decreased Impax Laboratories Inc (IPXL) stake by 28.35% reported in 2017Q3 SEC filing. Sector Gamma As sold 167,050 shares as Impax Laboratories Inc (IPXL)’s stock rose 7.88%. The Sector Gamma As holds 422,261 shares with $8.57 million value, down from 589,311 last quarter. Impax Laboratories Inc now has $1.43 billion valuation. The stock decreased 0.26% or $0.05 during the last trading session, reaching $19.25. About 134,712 shares traded. Impax Laboratories, Inc. (NASDAQ:IPXL) has declined 49.01% since January 17, 2017 and is downtrending. It has underperformed by 65.71% the S&P500.

Devon Energy Corporation, an independent energy company, primarily engages in the exploration, development, and production of oil, natural gas, and natural gas liquids in the United States and Canada. The company has market cap of $22.53 billion. It operates approximately 15,200 gross wells. It has a 14.59 P/E ratio. The firm also offers gathering, transmission, processing, storage, fractionation, and marketing to upstream oil and natural gas producers; and owns natural gas pipelines, plants and treatment facilities.

Ratings analysis reveals 60% of Devon Energy’s analysts are positive. Out of 5 Wall Street analysts rating Devon Energy, 3 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. DVN was included in 5 notes of analysts from September 6, 2016. Seaport Global Securities upgraded the shares of DVN in report on Friday, December 9 to “Buy” rating. The firm has “Buy” rating by Societe Generale given on Thursday, February 16. On Tuesday, September 6 the stock rating was downgraded by Raymond James to “Mkt Perform”. On Tuesday, January 17 the stock rating was downgraded by Jefferies to “Hold”. The rating was initiated by Stifel Nicolaus with “Buy” on Thursday, April 13.

Analysts await Devon Energy Corporation (NYSE:DVN) to report earnings on February, 13. They expect $0.58 EPS, up 132.00% or $0.33 from last year’s $0.25 per share. DVN’s profit will be $304.79 million for 18.48 P/E if the $0.58 EPS becomes a reality. After $0.46 actual EPS reported by Devon Energy Corporation for the previous quarter, Wall Street now forecasts 26.09% EPS growth.

The stock decreased 0.90% or $0.39 during the last trading session, reaching $42.87. About 1.13M shares traded. Devon Energy Corporation (DVN) has risen 13.24% since January 17, 2017 and is uptrending. It has underperformed by 3.46% the S&P500.

First Reserve Gp Xii Ltd holds 17.33% of its portfolio in Devon Energy Corporation for 1.34 million shares. Key Group Holdings (Cayman) Ltd. owns 1.68 million shares or 6.71% of their US portfolio. Moreover, Sir Capital Management L.P. has 5.67% invested in the company for 1.20 million shares. The Texas-based Mitchell Group Inc has invested 5.31% in the stock. Stuyvesant Capital Management, a New York-based fund reported 65,680 shares.

Investors sentiment increased to 1.75 in Q3 2017. Its up 0.85, from 0.9 in 2017Q2. It increased, as 14 investors sold IPXL shares while 39 reduced holdings. 39 funds opened positions while 54 raised stakes. 65.84 million shares or 4.79% more from 62.83 million shares in 2017Q2 were reported. 64,870 are owned by State Of Tennessee Treasury Department. Louisiana State Employees Retirement Sys has 30,100 shares. Reilly Fincl Lc holds 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL) for 500 shares. Suntrust Banks has 0% invested in Impax Laboratories, Inc. (NASDAQ:IPXL) for 10,000 shares. Alps Advsr Incorporated accumulated 73,186 shares. Point72 Asset Management LP invested 0.09% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). The Maryland-based Burt Wealth Advsr has invested 0.01% in Impax Laboratories, Inc. (NASDAQ:IPXL). Deutsche Bancshares Ag stated it has 278,196 shares or 0% of all its holdings. Texas-based Maverick Limited has invested 1.67% in Impax Laboratories, Inc. (NASDAQ:IPXL). 38,042 were reported by Cubist Systematic Strategies Ltd. Bridger Mngmt Limited Liability Corporation invested in 0.73% or 602,456 shares. California Public Employees Retirement System holds 117,000 shares or 0% of its portfolio. Profund Advisors Ltd Liability Corp, Maryland-based fund reported 16,974 shares. Ameritas Prtnrs owns 6,324 shares or 0.01% of their US portfolio. Texas Permanent School Fund stated it has 0.01% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL).

Sector Gamma As increased Lexicon Pharmaceuticals Inc stake by 114,798 shares to 737,453 valued at $9.06 million in 2017Q3. It also upped Patterson Companies Inc (NASDAQ:PDCO) stake by 10,100 shares and now owns 396,332 shares. Boston Scientific Corp (NYSE:BSX) was raised too.

Among 21 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 6 have Buy rating, 2 Sell and 13 Hold. Therefore 29% are positive. Impax Laboratories Inc. had 47 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) has “Neutral” rating given on Tuesday, July 18 by PiperJaffray. Northland Capital upgraded the stock to “Outperform” rating in Monday, August 15 report. Piper Jaffray maintained Impax Laboratories, Inc. (NASDAQ:IPXL) on Friday, September 15 with “Hold” rating. The stock has “Sector Perform” rating by RBC Capital Markets on Thursday, November 10. The stock has “Hold” rating by BMO Capital Markets on Friday, June 23. The stock has “Positive” rating by Susquehanna on Tuesday, July 21. Northland Capital initiated the stock with “Market Perform” rating in Tuesday, April 19 report. The rating was maintained by UBS on Monday, October 30 with “Sell”. The stock of Impax Laboratories, Inc. (NASDAQ:IPXL) earned “Hold” rating by RBC Capital Markets on Thursday, August 10. Cowen & Co maintained Impax Laboratories, Inc. (NASDAQ:IPXL) on Friday, November 10 with “Hold” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *